Regorafenib is a novel oral multikinase inhibitor of both intracellular and membrane-bound receptor-tyrosine kinases (RTKs), which involved in the signal pathways related to tumor angiogenesis, oncogenesis, tumor microenvironment and tumor growth/proliferation [2, 3]. This evidence concerns the gene NTRK1 and neoplasm.